Patients are arriving with questions that didn’t exist in primary care a decade ago: Should I be on NAD+? Will epitalon lengthen my telomeres? Is GHK-Cu worth it? They have usually read a podcast transcript or a longevity influencer’s protocol before they reach your exam room, and they want a clinician who can separate signal from hype. For nurse practitioners building an anti-aging or functional-medicine practice, that demand is an opportunity — but only if the clinical framing is honest. The science of longevity peptides is genuinely interesting and genuinely early. Most of the compounds in this space are not FDA-approved for anti-aging indications, and the human evidence ranges from promising to thin. This guide gives NPs a structured, evidence-candid way to think about the leading anti-aging peptides, the mechanisms patients are asking about, and where formal competency training fits. 

The Longevity-Science Framing: What “Anti-Aging Peptides” Actually Target 

Modern geroscience reframes aging not as one process but as a set of interacting cellular mechanisms — often summarized as the hallmarks of aging (genomic instability, telomere attrition, mitochondrial dysfunction, cellular senescence, loss of proteostasis, and altered nutrient sensing, among others).[^hallmarks2013][^hallmarks2023] The original 2013 framework described nine hallmarks; a 2023 update expanded the set to twelve, adding disabled macroautophagy, chronic inflammation, and dysbiosis. 

This matters clinically because the peptides patients ask about are, in theory, aimed at one or more of these pathways rather than at “aging” as a whole: 

• NAD+ precursors → mitochondrial function and cellular energetics / sirtuin signaling 

• Epitalon → telomere/telomerase and circadian (pineal) regulation 

• GHK-Cu → tissue remodeling, gene-expression modulation, and skin/extracellular-matrix repair 

• GH secretagogues (sermorelin, ipamorelin, CJC-1295) → the GH/IGF-1 axis as it relates to body composition and recovery — covered in depth in our companion guide on GH secretagogues 

The honest framing to give patients: these are hypothesis-driven interventions targeting aging biology. None has demonstrated extended human lifespan in controlled trials, and that should be stated plainly in any consultation. 

NAD+ and Its Precursors (NMN, NR): The Mitochondrial Story 

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme central to mitochondrial energy production and to the activity of sirtuins and PARP enzymes involved in DNA repair. Tissue and cellular NAD+ levels decline gradually with age across multiple model organisms, including rodents and humans — a decline that has been linked to several aging-associated conditions and is the rationale for supplementing its precursors — nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) — or administering NAD+ directly via IV or injection.[^naddecline] 

What the evidence supports, and what it doesn’t: 

• Oral NR and NMN raise blood NAD+ levels in human randomized trials — the pharmacologic premise is real. A randomized, placebo-controlled crossover trial of NR in healthy middle-aged and older adults found it was well tolerated and elevated NAD+ metabolism,[^martens] and a randomized, placebo-controlled trial of NMN in prediabetic women reported increased muscle insulin sensitivity.[^yoshino] 

• Clinical endpoint data are limited. Small and short human trials have explored metabolic, vascular, and physical-function outcomes with mixed and modest results; large, long-term outcome trials are lacking. 

• NAD+ is not a peptide — it is a nucleotide coenzyme. It is grouped here because patients (and many clinics) lump it into “peptide/longevity” menus, and NPs need to be precise about the distinction. 

• Regulatory status has been volatile. In 2022 the FDA took the position that NMN was excluded from the dietary-supplement definition because it had been authorized for investigation as a new drug. The agency reversed that position in two letters dated September 29, 2025, concluding that NMN is not excluded from the dietary-supplement definition — though it remains a New Dietary Ingredient subject to premarket notification requirements.[^fdanmn] IV NAD+ is typically a compounded preparation. Because this status has shifted before, verify the current FDA position before relying on it clinically. 

Counseling point: NAD+ is among the better-characterized longevity interventions on the mechanism side, but “raises NAD+” is not the same as “extends healthspan.” Keep the claim proportionate to the data. 

Epitalon: Telomeres, the Pineal Gland, and a Thin Evidence Base 

Epitalon (also spelled epithalon) is a synthetic tetrapeptide derived from epithalamin, a pineal-gland extract studied primarily by Russian researchers. The proposed mechanisms are striking: activation of telomerase, with downstream effects on telomere length, plus modulation of circadian/melatonin rhythms. An early in vitro study reported that epitalon induced telomerase activity and telomere elongation in human somatic (fetal fibroblast) cells.[^khavinson] Notably, much of this foundational work originates from a single research lineage and has seen limited independent replication. 

This is where candor matters most. The epitalon literature is a clear example of early-stage, low-quality evidence: 

• The human and animal studies appear largely small, older, and concentrated in one research lineage, with limited independent replication in peer-reviewed Western journals.[^khavinson] 

• It has no FDA approval and is not an approved drug in the US; products marketed to consumers are typically research-use-only or compounded. 

• Claims that epitalon “lengthens telomeres and extends lifespan” in humans outrun the controlled-trial evidence and should not be presented to patients as established. 

For an NP, epitalon is a useful teaching case in evidence literacy: an intriguing mechanism, a compelling narrative, and a body of data too thin to support strong clinical claims. 

GHK-Cu: The Copper Peptide With the Most Tangible Data 

GHK-Cu (copper tripeptide-1, glycyl-L-histidyl-L-lysine bound to copper) is the longevity peptide with the most concrete and reproducible evidence — though largely outside the systemic-aging arena. GHK is a naturally occurring peptide whose plasma levels decline with age, and it has been studied for wound healing, skin remodeling, anti-inflammatory and antioxidant activity, and broad gene-expression modulation — with reviews reporting that GHK-Cu can meaningfully alter the expression of a large fraction of human genes.[^pickart] 

Clinical reality for NP practice: 

• The strongest evidence is topical/dermatologic and regenerative — skin firmness, wound repair, hair-related applications — much of it in vitro or in small studies. Systemic “anti-aging” or longevity claims are far less substantiated. 

• GHK-Cu appears in many cosmetic and compounded formulations; quality, concentration, and route vary widely, which directly affects what you can responsibly tell a patient to expect. 

• It is frequently the most patient-relevant of the longevity peptides because the proposed benefits (skin, tissue repair) are visible and near-term rather than speculative lifespan claims. 

Where GH Secretagogues Fit in the Longevity Conversation 

Patients often fold sermorelin, ipamorelin, and CJC-1295 into “anti-aging” because of their effects on the growth hormone/IGF-1 axis, body composition, sleep, and recovery. The nuance NPs should hold: the GH/IGF-1 axis has a complicated relationship with longevity — in model organisms, reduced GH/IGF-1 signaling is often associated with extended lifespan, even as GH optimization can improve body composition and quality-of-life markers in adults.[^ghigf1] 

In other words, “more GH = slower aging” is an oversimplification. Because the prescribing, dosing, and monitoring considerations for secretagogues are substantial, we cover them separately in the GH secretagogues comparison guide. For the foundational pharmacology of how peptides work as a therapeutic class, see our clinical primer on peptide therapy. 

Candid Evidence Assessment: A Tier Map for Counseling 

A defensible way to frame the category for patients and for your own documentation: 

[!warning] YMYL framing — keep claims proportionate Longevity and anti-aging peptide evidence is largely early-stage. Most of these compounds are not FDA-approved for anti-aging indications, and several are compounded or research-use-only. Present mechanisms as hypotheses, not as established clinical outcomes, and document accordingly. 

Patient Selection and Counseling Considerations 

Anti-aging peptide requests are some of the most expectation-laden conversations in a cash-pay practice. A structured approach: 

• Lead with workup, not the menu. Optimize the fundamentals first — sleep, metabolic health, body composition, thyroid and sex-hormone status, and modifiable risk — before layering on experimental peptides. 

• Set evidence-calibrated expectations. Distinguish “supported mechanism” from “proven outcome,” and tell patients directly when something is early-stage. This is both good care and liability protection. 

• Document off-label/compounded use and consent. For off-label, compounded, or research-use-only products, the prudent standard is to document the off-label nature of the therapy and obtain and record informed consent; specific requirements vary by state, so verify with your Board of Nursing.[^scope] 

• Know the source and quality. Compounded peptides should come from reputable 503A/503B pathways; “research-use-only” sourcing is a red flag for patient use. (Our companion guide details FDA status by compound — link in the conclusion.) 

• Stay inside your scope. NP scope of practice and prescriptive authority vary by state — verify current rules with your Board of Nursing, along with any controlled-substance considerations, before adding these services.[^scope] 

Where Structured Competency Training Fits 

The gap between knowing what these peptides are and responsibly counseling and (where appropriate) prescribing them is exactly where most NPs need structured training. Self-directed reading rarely covers patient selection frameworks, the honest evidence hierarchy, sourcing and compounding pathways, informed-consent architecture, and monitoring in one coherent, ANCC-aligned curriculum. 

The Anti-Aging & Peptide Course is built specifically for nurse practitioners and treats longevity peptides the way this article does — mechanism-first, evidence-honest, and oriented toward defensible practice rather than hype. It is the structured pathway for turning patient demand into competent, well-documented care. 

Frequently Asked Questions 

What are the best anti-aging peptides? 

There is no evidence-established “best” anti-aging peptide. The most-discussed are NAD+ precursors (NMN, NR), epitalon, and GHK-Cu, plus growth-hormone secretagogues. GHK-Cu has the most reproducible data (largely for skin and tissue repair), and NAD+ precursors have the best-supported mechanism, but none has been proven to extend human lifespan in controlled trials. 

Is NAD+ a peptide? 

No. NAD+ (nicotinamide adenine dinucleotide) is a coenzyme, not a peptide. It is frequently grouped with longevity peptides because clinics offer it alongside them, but NPs should keep the distinction clear when counseling patients. 

Does epitalon actually lengthen telomeres? 

Epitalon is proposed to activate telomerase, and some early studies report effects on telomere length. However, the human evidence is small, dated, and largely unreplicated in independent peer-reviewed journals. Claims that epitalon lengthens telomeres and extends lifespan in humans are not supported by robust controlled-trial data. 

Are anti-aging peptides FDA-approved? 

Most are not approved for anti-aging or longevity indications. Many are compounded or sold as research-use-only products, and regulatory status varies by compound. NPs should verify the current FDA status of any specific peptide before clinical use. 

Can nurse practitioners offer longevity and anti-aging peptide services? 

In many settings, yes — within state scope of practice and with appropriate training, sourcing, and informed consent. Because rules vary by state and several products are off-label or compounded, NPs should verify current requirements with their state Board of Nursing and pursue structured competency training before adding these services. 

Conclusion 

Longevity peptides sit at the intersection of real science and real hype. NAD+ precursors have a credible mechanism, GHK-Cu has the most tangible (mostly regenerative) data, and epitalon remains an intriguing but thinly evidenced compound — none a proven path to a longer human life. The NP’s value is precisely this calibration: meeting patient demand with honest, evidence-weighted counseling and defensible documentation. If you want to offer these services competently, build the framework deliberately. 

→ Build evidence-honest longevity competency with the Anti-Aging & Peptide Course. 

Sources 

All sources accessed 2026-06-26. 

López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013;153(6):1194–1217. doi:10.1016/j.cell.2013.05.039. PMID: 23746838. PubMed · PMC full text 

López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: an expanding universe. Cell. 2023;186(2):243–278. doi:10.1016/j.cell.2022.11.001. PMID: 36599349. PubMed 

Covarrubias AJ, Perrone R, Grozio A, Verdin E. NAD+ metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol. 2021;22(2):119–141. doi:10.1038/s41580-020-00313-x. PMID: 33353981. PubMed · PMC full text 

Martens CR, Denman BA, Mazzo MR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9(1):1286. doi:10.1038/s41467-018-03421-7. PMID: 29599478. PubMed 

Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224–1229. doi:10.1126/science.abe9985. PMID: 33888596. PubMed 

U.S. Food and Drug Administration. Constituent update / NDI determination letters regarding β-nicotinamide mononucleotide (NMN), dated September 29, 2025 (reversing the agency’s 2022 position that NMN was excluded from the dietary-supplement definition; NMN treated as not excluded but remaining a New Dietary Ingredient subject to premarket notification). FDA, 2025. See also U.S. FDA letter (2022), regulations.gov. Status summary: NutraIngredients-USA, 2025-09-30 and Venable LLP analysis, 2025-10. Regulatory status has shifted before — verify the current FDA position at the time of use. 

Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):692–695. doi:10.1023/A:1025493705728. Springer (article record). Note: this and most early epitalon work originate from a single research lineage with limited independent peer-reviewed replication in Western journals. 

Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987. doi:10.3390/ijms19071987. PMID: 29986520. PubMed 

Junnila RK, List EO, Berryman DE, Murrey JW, Kopchick JJ. The GH/IGF-1 axis in ageing and longevity. Nat Rev Endocrinol. 2013;9(6):366–376. doi:10.1038/nrendo.2013.67. PMID: 23591370. PubMed · PMC full text 

NP scope of practice, prescriptive authority, and informed-consent/documentation requirements vary by state and are set by each state’s Nurse Practice Act and Board of Nursing; verify current rules with your state Board of Nursing. National reference index: NCSBN — Boards of Nursing directory and the AANP State Practice Environment.